ANN ARBOR, Mich. — ANN ARBOR, Mich. (AP) — Esperion Therapeutics Inc. (ESPR) on Tuesday reported a loss of $55.5 million in its fourth quarter.

On a per-share basis, the Ann Arbor, Michigan-based company said it had a loss of 76 cents.

The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 87 cents per share.

The biopharmaceutical company posted revenue of $18.8 million in the period, which fell short of Street forecasts.

Six analysts surveyed by Zacks expected $20 million.

For the year, the company reported that its loss narrowed to $233.7 million, or $3.52 per share. Revenue was reported as $75.5 million.